Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.47M | 3.58M | 4.68M | 4.77M | 4.87M |
| Total Depreciation and Amortization | 6.03M | 6.02M | 6.02M | 6.27M | 6.54M |
| Total Amortization of Deferred Charges | 830.90K | 824.70K | 821.00K | 825.70K | 833.30K |
| Total Other Non-Cash Items | 11.27M | 6.39M | 1.59M | 1.20M | 830.10K |
| Change in Net Operating Assets | 5.34M | 5.34M | 5.34M | 4.33M | 3.35M |
| Cash from Operations | 25.94M | 22.15M | 18.45M | 17.39M | 16.42M |
| Capital Expenditure | -4.83M | -4.01M | -3.22M | -3.42M | -3.63M |
| Sale of Property, Plant, and Equipment | 32.60K | 32.60K | 32.60K | 153.80K | 275.80K |
| Cash Acquisitions | -- | -- | -- | 196.00K | 393.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.90K | 698.70K | 1.37M | 1.43M | 1.48M |
| Cash from Investing | -4.78M | -3.28M | -1.81M | -1.64M | -1.48M |
| Total Debt Issued | 327.12M | 358.42M | 389.73M | 354.56M | 319.40M |
| Total Debt Repaid | -415.20M | -424.41M | -433.62M | -410.97M | -388.32M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.96M | -12.99M | -14.02M | -14.31M | -14.60M |
| Cash from Financing | -14.47M | -11.21M | -8.03M | -9.79M | -11.58M |
| Foreign Exchange rate Adjustments | -468.00K | -278.10K | -91.60K | -600.00 | 90.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.23M | 7.38M | 8.51M | 5.95M | 3.44M |